Contraindicated in:
Use Cautiously in:
CV: PR interval prolongation, QT interval prolongation, TORSADES DE POINTES.
Derm: rash, STEVENS-JOHNSON SYNDROME.
Endo: hypoglycemia.
GI: abdominal cramps/pain, diarrhea, nausea, vomiting, hepatotoxicity.
GU: ↓fertility (males).
Hemat: bleeding, blood dyscrasias, hemolytic anemia, HEMOLYTIC UREMIC SYNDROME, THROMBOCYTOPENIA, THROMBOTIC THROMBOCYTOPENIC PUPURA.
Misc: cinchonism, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND FEVER).
Drug-Drug:
Renal Impairment
Absorption: Rapidly and almost completely (80%) absorbed following oral administration.
Distribution: Varies with condition and patient; does not enter CSF well. Crosses the placenta and enters breast milk.
Protein Binding: >90% in patients with cerebral malaria, pregnant women, and children; 8590% in patients with uncomplicated malaria; 70% in healthy adults.
Metabolism/Excretion: >80% metabolized by the liver; metabolites have less activity than quinine; metabolites excreted in urine. 20% excreted unchanged in urine. Excretion ↑ in acidic urine.
Half-life: 11 hr (↑ in patients with malaria).
NDC Code*